{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-039650","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.421339+00:00","generated_at":"2026-05-17T01:48:22.951406+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ionis Q3 revenue $157M, up 17% YoY; raises FY 2025 guidance on TRYNGOLZA strength","bullets":["TRYNGOLZA Q3 net sales $32M, ~70% QoQ increase; FY guidance raised to $85-95M.","Olezarsen Phase 3 sHTG: 72% TG reduction, 85% AP reduction; sNDA by year-end 2025.","Zilganersen positive pivotal in Alexander disease; NDA submission planned Q1 2026.","Total revenue guidance raised to $875-900M; non-GAAP op loss guided to $275-300M.","Cash and investments $2.2B as of Sep 30; DAWNZERA launched in August 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-039650","json":"https://secwatch.observer/filing/0001140361-25-039650.json","markdown":"https://secwatch.observer/filing/0001140361-25-039650.md","text":"https://secwatch.observer/filing/0001140361-25-039650.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/0001140361-25-039650-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125039650/ef20057869_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:48:22.951406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}